- Market Realist•44 minutes ago
With 80% of the total patients on antiretroviral therapy using the company’s HIV drugs in the US, Gilead Sciences (GILD) continues to be a leading player in the HIV segment.
|Bid||80.57 x 100|
|Ask||80.59 x 100|
|52wk Range||77.92 - 120.37|
|Day's Range||80.40 - 80.84|
|Avg Vol (3m)||10,212,511|
As of 9:49 AM EDT. NasdaqGS Real Time Price. Market open.